retatrutide south africa The Effect of on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity Retatrutide | GLP-1R/GIPR/GCGR ligand |

Specifically engineered to reach therapeutic levels within the plasma, ensuring a robust weekly defense against localized metabolic imbalances

Sudden onset, severe headache

It activates GLP-1, GIP, and glucagon receptors at the same time

FDA approval means GLP-1 medications are designed for adults with obesity or weight-related health risks

Paediatric patients who weigh greater than 60kg are also eligible for the drug to help with weight loss and weight maintenance

Exenatide was the worlds first clinically used GLP-1RA, developed in 1995 and approved for the treatment of type 2 diabetes mellitus (T2DM) in 2005 due to its proven ability to regulate postprandial glucose levels effectively (Min et al., 2025) necessitates twice-daily injections to maintain efficacy, which can be a limiting factor for long-term patient adherence